ADD-17014

ADD-17014 is a L-Glu antagonist. ADD-17014 impairs presynaptic excitatory amino acid L-Glu neurotransmission. ADD-17014 is a prodrug of its β-amino alcohol metabolite, and the metabolite acts as a NMDA receptor antagonist by binding to the MK-801 site located inside the NMDA receptor or ion channel. ADD-17014 has an anticonvulsant and anti-ischemic activity. ADD-17014 can be used for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease and stroke research[1][2].

Product Specifications

CAS Number

55643-87-3

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

MGluR

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

ClC1=CC=C(N2N=NCC2C3=CC=NC=C3)C=C1

Molecular Formula

C13H11ClN4

Molecular Weight

258.71

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Van der Schyf CJ, Gal S, et al. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs. 2006 Aug;15 (8) :873-86. |[2]Kadaba PK. Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents. Curr Med Chem. 2003 Oct;10 (20) :2081-108.